Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to asymptomatic (no symptoms) HIV-infected patients. Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the protein integrase to infect a cell. Integrase inhibitors block integrase and may stop replication of HIV.

Key facts

Study ID

NCT00002403

Run by

Aronex Pharmaceuticals

People needed

12

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are HIV-positive, but do not have any symptoms of HIV infection.
• Have a CD4 count greater than 200 cells/mm3.
• Have a viral load (level of HIV in the body) greater than 4,000 copies/ml.
• Are at least 18 years old.

You may not qualify if…

• You will not be eligible for this study if you:
• Tend to have abnormal bleeding or other blood problems.
• Have an active AIDS-defining illness.
• Have a history of serious disease or illness.
• Abuse alcohol or drugs.
• Have received certain medications.

Where it is running

• Cornell AIDS Clinical Trials Unit — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.